TICKERNERD
Menu
CNXUHealthcare · Biotechnology

CNXU Stock Forecast: Conexeu Sciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.90
−5.62% on the day

The 1 Wall Street analysts covering Conexeu Sciences, Inc. hold a median 12-month price target of $20 — +124.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$237.9M
Ticker Nerd rank
2 / 100
Median analyst target
$20
Analysts covering
1
Total return, dividends reinvested
1W
0.0%
1M
−7.8%
From high
−47.2%
From low
+22.4%
$7
$17
Range since 21 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

CNXU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Conexeu Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
66
Revisions
45
Issuance
22
Growth
8
Accruals
8
Value
6
Momentum
4
Volatility
1
Quality
1

Size (66): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNXU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNXU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 21 May 2026Adjusted close, US dollars
$10$15$20Jun 26Jul 26Aug 26CNXUHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +124.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 June 2026HC Wainwright & Co.InitiatesBuy$20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNXU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CNXU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Conexeu Sciences, Inc. (CNXU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−46.4×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
25.8×

Cheaper than 4% of US stocks

EV / EBITDA
−32.1×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−53.4%

Higher than 20% of US stocks

Return on assets
−51.0%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CNXU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNXUConexeu Sciences, Inc.$237.9M
2
SIONSionna Therapeutics, Inc.$236.1M
32
DTILPrecision BioSciences, Inc.$244.3M
70
GLSIGreenwich LifeSciences, Inc.$244.7M
41
CGENCompugen Ltd.$247.3M
82
ABOSAcumen Pharmaceuticals, Inc.$228.2M
44
TARAProtara Therapeutics, Inc.$227.5M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Conexeu Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNXU news & analysis

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

GlobeNewsWire · 18 Aug 2026positive

The article reports that peer-reviewed research is pointing to the extracellular matrix as central to regenerative work in medical aesthetics, and notes that more than a decade of research has gone into Conexeu Sciences' CXU™ Platform. A new category is described as forming in the field as research turns toward regeneration.

Why it matters — CNXU watchers would care because the piece highlights the depth of research behind Conexeu's CXU™ Platform and positions the company within an emerging regenerative category in medical aesthetics.

FAQ

Frequently asked questions about CNXU stock

What is the CNXU stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Conexeu Sciences, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNXU stock a buy right now?

Of the 1 analysts covering Conexeu Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Conexeu Sciences, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNXU?

As at 22 Aug 2026, Conexeu Sciences, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (66 of 100).

Will CNXU stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +124.7% from the last close, and Ticker Nerd's factor model ranks Conexeu Sciences, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNXU stock forecast for 2030?

No analyst covering Conexeu Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNXU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

What does Conexeu Sciences, Inc. do?

Conexeu Sciences Inc. is a biotechnology company focused on developing and commercializing therapies in the life sciences and healthcare sector.

What is the latest news on CNXU?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration". The article reports that peer-reviewed research is pointing to the extracellular matrix as central to regenerative work in medical aesthetics, and notes that more than a decade of research has gone into Conexeu Sciences' CXU™ Platform. A new category is described as forming in the field as research turns toward regeneration.

Company

About Conexeu Sciences, Inc.

Conexeu Sciences Inc. is a biotechnology company focused on developing and commercializing therapies in the life sciences and healthcare sector. The company concentrates on innovative treatments that aim to address unmet medical needs, leveraging scientific research, clinical development, and regulatory expertise. Conexeu Sciences Inc. typically works across key therapeutic areas where biologics, small molecules, or advanced modalities such as gene or cell-based approaches can play a meaningful role. Its activities span preclinical research, clinical trials, and collaboration with healthcare providers, research institutions, and industry partners to advance candidate therapies toward approval and medical adoption. Founded in the United States, Conexeu Sciences Inc. participates in a highly specialized segment of the healthcare market, where scientific rigor, intellectual property, and regulatory compliance are central to its operations. The company’s role in the financial markets reflects investor interest in the biotechnology industry, which is characterized by a focus on innovation, scientific data, and progress in clinical development programs.

CEO Mr. Miles D. Harrison · United States · https://www.conexeu.com